abrdn Life Sciences Investors
HQL
56 hedge funds and large institutions have $54.8M invested in abrdn Life Sciences Investors in 2019 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 21 increasing their positions, 20 reducing their positions, and 8 closing their positions.
11% more capital invested
Capital invested by funds: $49.3M → $54.8M (+$5.47M)
5% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 20
0.28% less ownership
Funds ownership: 14.82% → 14.53% (-0.28%)
5% less funds holding
Funds holding: 59 → 56 (-3)
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
+$756K |
| 2 |
1WA
180 Wealth Advisors
Federal Way,
Washington
|
+$611K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$510K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$416K |
| 5 |
FHA
Flagship Harbor Advisors
Boston,
Massachusetts
|
+$234K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$660K |
| 2 |
Invesco
Atlanta,
Georgia
|
-$573K |
| 3 |
SI
Stephens Inc
Little Rock,
Arkansas
|
-$454K |
| 4 |
CAN
Claraphi Advisory Network
Aliso Viejo,
United States
|
-$399K |
| 5 |
AAM
Advisors Asset Management
Monument,
Colorado
|
-$394K |
HQL Hedge Fund Activity: Q1 2019 in Review
56 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in abrdn Life Sciences Investors (HQL) for Q1 2019, worth a combined $54.8M — up 11% from $49.3M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of HQL and 5 opened new positions — a net loss of 3 holders — while 20 trimmed existing stakes and 21 added.
The largest buyer was Wolverine Asset Management, adding an estimated $756K. The largest seller was Morgan Stanley, cutting an estimated $660K.
- 56 institutional investors held abrdn Life Sciences Investors (HQL) as of Q1 2019, down from 59 in Q4 2018.
- Funds reported $54.8M of abrdn Life Sciences Investors stock for Q1 2019, up 11% quarter-over-quarter.
- 5 funds opened new abrdn Life Sciences Investors positions in Q1 2019 and 8 closed out, a net change of -3 holders.
- The largest abrdn Life Sciences Investors buyer in Q1 2019 was Wolverine Asset Management, an estimated $756K added.
- The largest abrdn Life Sciences Investors seller in Q1 2019 was Morgan Stanley, an estimated $660K sold.
Based on aggregated 13F filings for Q1 2019.